Ebola Virus Disease (EVD) Vaccines Would Gain A Market Value of $56 Million by 2020

Date: 2015-06-11

“Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020″”, anticipates that the Ebola Virus Disease (EVD) vaccines would gain a market value of $56 million by 2020. The rampant growth of the disease in the under developed economics and increasing awareness among people about life threatening EVD disease has motivated healthcare authorities to introduce novel therapeutics.Ebola, an orphan disease, has affected more than 20,000 people in the African countries as of now. Recurring outbreaks of Ebola in under developed region and lack of effective therapies are factors that drive the need for Ebola drugs and vaccines. The perennial outbreak of Ebola has given rise to a renewed interest among healthcare authorities in finding effective therapies. To control the EVD, the government authorities are supplying funds to pharmaceutical companies for research and development of EVD drugs and vaccines. As an example, government of the United States, through the FDA, has granted “Fast Track” designation to the Tekmira’s TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, “The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by provid 
ing funds and floating favorable policies”.
Normal symptoms such as simple viral fever are initially observed in patients infected with EVD’s; however, at later stages, the consequences of these symptoms become deadly and leave no space for recovery. In United States, EVD is termed as Quarantinable Communicable Diseases under section 361(b) of the Public Health Service Act. This report tracks such key regulatory road maps and anticipated regulations in future by respective administrations. The report also focuses on the grass root ethical implications faced by players during clinical trials and other commercial activities.Developed economies are interested in formulating therapeutics that can significantly minimize threats from Ebola virus. Companies operating in this market are currently focusing on clinical trials as a key strategy. The commercialization of Ebola therapeutics is the prime focus of healthcare systems, as there are no specific medications available in the market. Companies profiled in the report are Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics Corp and Mapp Biopharmaceutical.”


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample